Insights
Benchmark International Successfully Facilitated the Transaction Between Community Pharmacology Services Limited and FutureMeds Sp. z o.o.
September 14, 2023
Benchmark International is pleased to announce the acquisition of Glasgow-based Community Pharmacology Services (CPS Research) by FutureMeds.
CPS Research conducts phase II-IV clinical trials and has over 30 years of clinical research experience. With a reach throughout the central belt of Scotland, the CPS team has conducted over 250 studies across a wide range of therapeutic areas and indications, such as cardiology, endocrinology, gastroenterology, gynaecology, orthopaedics, psychiatry, immunology, dermatology, and respiratory medicine.
FutureMeds is the first European dedicated decentralised clinical trial (DCT) site network. Through acquisitions and a strategic focus on patient experience, FutureMeds has developed large, qualified patient pools across Europe that enable faster patient enrolment, stronger retention and more accurate results.
This expansion promises to bring enhanced solutions to clients and accelerated access to new treatments for patients. CPS Research has over 4,000 engaged patients in the database, and with the FutureMeds DCT toolkit, the catchment area can be extended over the Glasgow urban area.
Post acquisition, co-founders of CPS Research, Dr Alan Wade MBCHB FRCA and Dr Gordon Crawford BSC MBCHB MRCGP, will embark on a new chapter within a year, while general manager, Craig McCallum, will continue to lead the research team. His goal is to expand the team's relationships with local communities, amplify the site’s impact in driving medical progress and improve patients' access to new treatments.
Mr McCallum said: “As we bring together our wealth of experience to the ultimate benefit of our clients and patients, we are truly excited for the future and what we will be able to achieve as part of such a growing powerhouse of medical research.”
Dr Crawford added: "Having developed CPS Research with Alan, we are delighted to see it become part of the growing FutureMeds Site Network. By contributing to medical progress, we are sure CPS Research's team will build on our legacy and continue to thrive as one of the best dedicated research centres in the UK."
John Allen, managing director at FutureMeds commented: “The addition of CPS Research marks a significant milestone for our clients, volunteers and teams. CPS Research has a reputable standing in the industry, boasting over three decades of expertise overseeing and conducting clinical trials. We are thrilled to welcome their knowledgeable team into our fold.”
Share This Post
Categories
Get These Insights Delivered Directly To Your Email
Explore our curated collection today and stay ahead of the curve in M&A.
Verwandte Artikel
Benchmark International Announces Tyrus O’Neill as New Chief Executive Officer (CEO) of the AmericasTAMPA, FL – 03/14/2025 – Benchmark International, a leading global mergers and acquisitions (M&A) advisory firm, is excited to announce Tyrus O’Neill as the new Chief Executive Officer (CEO) of the Americas. The appointment is part of Benchmark International’s ongoing strategy to accelerate its global growth and service innovation.Erwartungen für Fusionen und Übernahmen im mittleren Marktsegment im Jahr 2025Jüngste Umfragen haben gezeigt, dass die M&A-Aussichten für das Jahr 2025 den größten Optimismus der letzten Jahre in Bezug auf Geschäftsabschlüsse erkennen lassen. Die 14. jährliche Umfrage der Citizens Bank unter mehr als 400 Führungskräften des Mittelstands und Private-Equity-Investoren in den Vereinigten Staaten ergab, dass ein günstiges wirtschaftliches Umfeld ein Hauptgrund dafür ist, dass Unternehmen und Investoren im Jahr 2025 nach M&A-Strategien suchen werden. Außerdem haben sich die Unsicherheiten der letzten Jahre gelegt, und die Bewertungen werden als stabil oder höher als in den vergangenen Jahren eingeschätzt. Kleinere mittelständische Unternehmen gehen indes zurückhaltender vor, und viele Verkäufer entscheiden sich für den Verkauf eines Teils ihres Unternehmens und nicht für einen Komplettverkauf. Zusammenfassend lässt sich sagen, dass die befragten Entscheidungsträger für das Jahr 2025 ein Wirtschaftswachstum und eine höhere Rate an M&A-Transaktionen erwarten.